ReShape Lifesciences (OTCMKTS:RSLSD – Get Free Report) and Vyome (NASDAQ:HIND – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Volatility and Risk
ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Vyome has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Institutional and Insider Ownership
22.1% of Vyome shares are owned by institutional investors. 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ReShape Lifesciences | 0 | 0 | 0 | 0 | 0.00 |
| Vyome | 0 | 0 | 2 | 0 | 3.00 |
Vyome has a consensus target price of $15.00, indicating a potential upside of 181.43%. Given Vyome’s stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than ReShape Lifesciences.
Earnings and Valuation
This table compares ReShape Lifesciences and Vyome”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ReShape Lifesciences | $610,000.00 | 0.00 | -$81.15 million | N/A | N/A |
| Vyome | $8.01 million | 0.45 | -$7.13 million | ($433.08) | -0.01 |
Vyome has higher revenue and earnings than ReShape Lifesciences.
Profitability
This table compares ReShape Lifesciences and Vyome’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ReShape Lifesciences | -668.58% | -163.22% | -52.10% |
| Vyome | -69.71% | -216.95% | -69.42% |
Summary
Vyome beats ReShape Lifesciences on 8 of the 11 factors compared between the two stocks.
About ReShape Lifesciences
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
About Vyome
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
